Wednesday, 05 October 2022

 

 

LATEST NEWS Kuljit Singh Randhawa inaugurates District Level Kisan Mela and Exhibition Vigilance arrests Inspector Punsup for taking bribe Jagat Prakash Nadda and Jai Ram Thakur visits AIIMS at Kothipura Tanzanian social media influencer Kili Paul all set to enter 'Bigg Boss 16' Administration Gear-up to tackle the issue of Stubble burning Women's T20I Player Rankings : Jemimah Rodrigues jumps four places to reach eighth position Legends League Cricket : Mohammad Kaif recreates memory of Pakistan match, netizens go crazy AAP slams BJP for not releasing pending dues of sugarcane farmers in Gujarat and UP Ranveer Singh releases DSP's first non-film Hindi track 'O Pari' Sharvi Yadav reacts to success of her songs 'The Hic Song', 'Step Copy' Uttarkashi Avalanche : 10 mountaineers killed, 8 climbers rescued so far IAF instructed to mount rescue operation in Uttarakhand : Rajnath Singh #FlipkartDoglaHai Trends On Twitter After Flipkart Starts Cancelling Orders, Delay In Shipping & Blocking Accounts World leaders labelled Imran Khan 'rude, liar and narcissist': Shehbaz Sharif 11 killed in Vadodara as truck collides with autorickshaw Will continue the hard work to further improve my game : hockey forward Mumtaz Khan Google probing why can't some Pixel owners use Android Auto Kajal and Zorawar Singh conferred with Miss and Mr Fresher 2022 titles at CGC Landran Amitabh Bachchan says people should inculcate discipline akin to that of the Indian army Assam : Drugs worth Rs 1 cr seized, three arrested 3 students drown, 2 missing on Andhra Pradesh beach

 

DRDO's anti-Covid drug 2-DG launched

Coronavirus, COVID 19, Novel Coronavirus, Fight Against Corona, Covaxin, Covishield, Covid-19 Vaccine, Oxygen, #OxygenCylinders, #oxygen, Oxygen Cylinders, SARS-CoV-2, Sputnik V, Oxygen Plants, Pfizer, Astra Zeneca, Oxygen Concentrator, Remdesivir, Covifor, Oxygen supply, DRDO, Defence Research and Development Organisation

Web Admin

Web Admin

5 Dariya News

New Delhi , 17 May 2021

The first batch of DRDO-developed anti-Covid drug 2-DG (2-deoxy-D-glucose) was launched on Monday to treat patients suffering from the deadly disease. The medicine comes in powder form and can be taken with water.Defence Minister Rajnath Singh and Health Minister Harsh Vardhan released the first batch of the 2-DG, an anti-Covid-19 therapeutic application of the drug developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO) in collaboration with Dr Reddy's Laboratories (DRL).Rajnath Singh handed over the anti-Covid drug to his cabinet colleague Harsh Vardhan who handed over it to Delhi All India Institute of Medical Sciences (AIIMS) director Randeep Guleria at an event here.The Defence Minister would be later distributing around 10,000 doses of the drug to a few hospitals in the national capital.The Drugs Controller General of India (DCGI) granted emergency use nod for the drug last week. The drug could be a game-changer in the battle against pandemic as it helps in faster recovery of hospitalised patients and reduces oxygen dependence.

Clinical trial results have shown that the drug helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients.The medicine was found to be safe for Covid-19 patients in phase 2 trials, conducted between May and October last year. It was found to be effective in cutting short the hospital stays of Covid patients and reducing their supplemental oxygen dependence.During the first wave of the pandemic in April last year, INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad, and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth.Based on these results, the Drugs Controller General of India (DCGI) Central Drugs Standard Control Organisation (CDSCO) permitted Phase-II clinical trial of 2- DG in Covid-19 patients in May 2020. The DRDO, along with its industry partner DRL, Hyderabad, started the clinical trials to test the safety and efficacy of the drug in Covid-19 patients.In Phase-II trials (including dose ranging) conducted during May-October 2020, the drug was found to be safe in Covid-19 patients and showed significant improvement in their recovery. Phase-II was conducted in six hospitals and Phase IIb (dose ranging) clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients.

 

Tags: Coronavirus , COVID 19 , Novel Coronavirus , Fight Against Corona , Covaxin , Covishield , Covid-19 Vaccine , Oxygen , #OxygenCylinders , #oxygen , Oxygen Cylinders , SARS-CoV-2 , Sputnik V , Oxygen Plants , Pfizer , Astra Zeneca , Oxygen Concentrator , Remdesivir , Covifor , Oxygen supply , DRDO , Defence Research and Development Organisation

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2022 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD